title: Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
authors.affiliation: Department of Hematology and Medical Oncology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, University of Bologna, Bologna. Electronic address: pierluigi.zinzani@unibo.it.
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: Department of Hematology and Medical Oncology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, University of Bologna, Bologna.
authors.forename: E
authors.initials: E
authors.lastname: Derenzini
authors.affiliation: Department of Hematology and Medical Oncology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, University of Bologna, Bologna.
authors.forename: C
authors.initials: C
authors.lastname: Pellegrini
authors.affiliation: Department of Hematology, Azienda Ospedaliero-Universitaria Careggi, Firenze.
authors.forename: L
authors.initials: L
authors.lastname: Rigacci
authors.affiliation: Department of Hematology, Azienda Ospedaliero-Universitaria Senese, Siena.
authors.forename: A
authors.initials: A
authors.lastname: Fabbri
authors.affiliation: Department of Hematology and Medical Oncology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, University of Bologna, Bologna.
authors.forename: L
authors.initials: L
authors.lastname: Gandolfi
authors.affiliation: Department of Hematology and Medical Oncology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, University of Bologna, Bologna.
authors.forename: L
authors.initials: L
authors.lastname: Argnani
authors.affiliation: Department of Hematology and Medical Oncology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, University of Bologna, Bologna.
authors.forename: B
authors.initials: B
authors.lastname: Casadei
authors.affiliation: Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome.
authors.forename: A
authors.initials: A
authors.lastname: Pulsoni
authors.affiliation: Department of Hematology, Azienda Ospedaliero-Universitaria San Martino, Genova.
authors.forename: M
authors.initials: M
authors.lastname: Gobbi
authors.affiliation: Department of Hematology, S. Eugenio Hospital University "Tor Vergata," Rome.
authors.forename: A
authors.initials: A
authors.lastname: Perotti
authors.affiliation: Department of Hematology, S. Maria delle Croci Hospital, Ravenna.
authors.forename: A
authors.initials: A
authors.lastname: Zaccaria
authors.affiliation: Department of Hematology, La Cattolica University, Rome.
authors.forename: M T
authors.initials: MT
authors.lastname: Voso
authors.affiliation: Division of Hematology, Cagliari Hospital, Cagliari.
authors.forename: M G
authors.initials: MG
authors.lastname: Cabras
authors.affiliation: Department of Hematology, Federico II University, Naples, Italy.
authors.forename: A
authors.initials: A
authors.lastname: De Renzo
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D016499:Radioimmunotherapy / Q000379:methods*; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan; D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine